Polypharmacy in Elderly Patients: Managing Multiple Medications Safely

The Polypharmacy Crisis

Polypharmacy — typically defined as taking five or more medications simultaneously — affects approximately 40% of adults over 65 in the United States. Adults 65+ comprise 13% of the population but account for 34% of all prescription medicine expenditures. The average Medicare beneficiary sees 7 different physicians and fills prescriptions at 2+ pharmacies.

This fragmented care creates serious risks:

Medicine-medicine interactions: Probability of at least one interaction approaches 100% at 7+ medicines

Adverse medicine events: Leading cause of hospitalization in older adults (20-30% of hospital admissions)

Falls: Medications are involved in up to 40% of falls

Cognitive impairment: Anticholinergic and sedating medicines dramatically worsen dementia risk

Adherence breakdown: Complexity overwhelms patients, leading to dangerous misuse

---

Why Elderly Patients Are More Vulnerable

Age-related pharmacokinetic changes significantly alter how medicines behave in older patients:

Altered distribution:

Body fat increases (25% → 45% of body weight), increasing volume of distribution for fat-soluble medicines (benzodiazepines, opioids) — prolonging their effects

Total body water decreases — higher concentration of water-soluble medicines (digoxin, gentamicin) for the same dose

Serum albumin decreases — more free (active) medicine for highly protein-bound medications

Reduced hepatic metabolism:

Liver mass decreases 20-30%; blood flow decreases 35-40%

Phase I metabolism (CYP enzymes) reduced; Phase II (glucuronidation) relatively preserved

Reduced renal elimination:

GFR declines ~1 mL/min/year after age 40

Many medicines (digoxin, metformin, most antibiotics, NSAIDs) require dose adjustment as GFR falls

Serum creatinine underestimates renal impairment in elderly (less muscle mass = less creatinine production)

Pharmacodynamic changes:

Increased brain sensitivity to CNS medicines (opioids, benzodiazepines, anticholinergics)

Decreased baroreceptor sensitivity → greater orthostatic hypotension risk

Reduced cardiac reserve → more intolerant of negative inotropes or arrhythmogenic medicines

---

The Beers Criteria: Potentially Inappropriate Medications

The American Geriatrics Society Beers Criteria (updated 2023) identifies medications that are potentially inappropriate for adults 65+ due to unfavorable risk-benefit profiles in this population.

Highlighted Beers Criteria medicines:

Benzodiazepines (ALL — short and long-acting):

Reason: Increased sedation, cognitive impairment, delirium, falls, and fractures in older adults

Risk is dose-dependent and additive with other CNS depressants

Alternatives: CBT-I for insomnia; buspirone for anxiety; SSRI for GAD

Anticholinergic medicines:

First-generation antihistamines: diphenhydramine (Benadryl), hydroxyzine — cause delirium, cognitive impairment, urinary retention

Tricyclic antidepressants: amitriptyline, nortriptyline — high anticholinergic burden

Bladder antimuscarinics: oxybutynin especially (mirabegron is preferred alternative)

Antipsychotics with anticholinergic effects: chlorpromazine

NSAIDs (oral, especially indomethacin):

Increased GI bleeding risk (especially without PPI co-prescription)

Worsens hypertension and heart failure

Acute kidney injury in dehydration

Alternatives: acetaminophen for most pain; topical NSAIDs for localized joint pain

Muscle relaxants (cyclobenzaprine, methocarbamol, carisoprodol):

Poorly tolerated: sedation, anticholinergic effects, falls

Inadequate evidence for efficacy in back pain

Sulfonylureas (especially glibenclamide/glyburide):

Long-acting; unpredictable hypoglycemia risk (irreversible hypoglycemia reported)

Prefer shorter-acting glipizide or modern non-hypoglycemia-causing agents (DPP-4 inhibitors, SGLT2 inhibitors)

---

Deprescribing: The Art of Stopping Medications

Deprescribing — systematically reducing or stopping medications whose risks outweigh benefits — is one of the most important and underutilized tools in geriatric medicine.

Deprescribing framework (STOPP/START, FORTA): 1. Compile complete medication list (prescriptions + OTC + supplements) 2. For each medicine: What is the indication? Is the indication still present? Was the medicine appropriately monitored? 3. Calculate medicine burden: anticholinergic burden score, CNS medicine count, fall-risk medications 4. Prioritize: Which medications have the highest harm-to-benefit ratio now? 5. Communicate: Involve patient and caregivers in deprescribing decisions; discontinue one medicine at a time with monitoring

Medicines frequently identified for deprescribing in elderly:

PPIs started during acute illness and never stopped

Bisphosphonates after >5 years in low-risk patients

Statins in patients >80 with limited life expectancy or very advanced dementia

Antihypertensives causing symptomatic hypotension

Antipsychotics for behavioral symptoms of dementia (should be time-limited trials)